Miplyffa, arimoclomol
Miplyffa (arimoclomol) is FDA-approved, together with miglustat, for neurological symptoms of Niemann-Pick disease type C in people aged 2 and older. Not available where you live? Your doctor may be able to request it by named-patient import. Reserve Meds coordinates the US supply and paperwork and quotes your costs in writing first.
Named-patient access overview. Miplyffa is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Miplyffa
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Miplyffa
Miplyffa (arimoclomol) is manufactured by Zevra Therapeutics and indicated for Niemann-Pick disease type C (neurological manifestations). It is an oral small molecule approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Miplyffa
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Miplyffa for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Miplyffa is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Clinical trials and expanded access
Expanded access records for arimoclomol that were marked “Available” on 17 October 2026:
Whether a patient can join a trial or an expanded access program is decided by the study team or the manufacturer, together with the treating doctor. Reserve Meds does not run trials or supply investigational medicines. We can help you and your doctor read a listing and understand the route.
Access by country
Reserve Meds publishes a detailed country deep-dive for Miplyffa in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Miplyffa
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.
Frequently asked questions
How can I get Miplyffa if it is not approved or available in my country?
Reserve Meds coordinates US-sourced Miplyffa for patients through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for your country and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Miplyffa through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Miplyffa. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in your country, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Miplyffa through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Miplyffa to a patient?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Miplyffa to your treating physician or hospital pharmacy, with appropriate handling for the product.
How long does it take, and what does Miplyffa cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Miplyffa?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.